Company Overview of Oxagen Limited
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, the Russian Federation, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in Abingdon, United Kingdom.
99 Park Drive
Abingdon, OX14 4RY
Founded in 1996
44 12 3584 1561
44 1235 443301
Key Executives for Oxagen Limited
Oxagen Limited Key Developments
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Oxagen Limited, please visit www.oxagen.co.uk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.